Future cancer vaccines may target antigens derived not from standard coding regions, but from the "dark genome." Dr. Radvanyi highlights that retro-transposable elements and endogenous retroviruses, activated in cancer, represent a vast, untapped source of tumor-specific antigens for novel immunotherapies.

Radiopharmaceuticals can use the same molecular scaffold for diagnosing a tumor with one radionuclide and treating it with another. This "theranostic" strategy improves patient stratification and accelerates the transition from diagnosis to effective therapy.

Instead of just measuring the presence or quantity of proteins, new technology analyzes their physical proximity and co-localization on a cell's surface. This protein "geography" creates a unique spatial fingerprint that can more accurately distinguish healthy regenerating cells from residual cancer cells post-treatment.

To overcome on-target, off-tumor toxicity, LabGenius designs antibodies that act like biological computers. These molecules "sample" the density of target receptors on a cell's surface and are engineered to activate and kill only when a specific threshold is met, distinguishing high-expression cancer cells from low-expression healthy cells.

An individual tumor can have hundreds of unique mutations, making it impossible to predict treatment response from a single genetic marker. This molecular chaos necessitates functional tests that measure a drug's actual effect on the patient's cells to determine the best therapy.

Instead of creating therapies for hundreds of specific driver mutations, which vary widely between patients, Earli's platform targets downstream commonalities—the "hallmarks of cancer" like rapid cell proliferation. These pathways are where diverse mutations converge, creating a more universal and reliable target across different cancers.

The same cancer-driving mutation behaves differently depending on the cell's internal "wiring." For example, a drug targeting a mutation works in melanoma but induces resistance in colorectal cancer due to a bypass pathway. This cellular context is why genetic data alone is insufficient.

Glioblastoma isn't a single mass but has finger-like 'tentacles' (diffuse infiltration) extending into brain tissue. It is also genetically and cellularly diverse, meaning a single-pathway drug will inevitably miss many tumor cells, leading to rapid recurrence and treatment failure.

Fluorescence-guided surgery will evolve beyond simply lighting up tumors. Dr. Phil Low's team is developing different colored dyes to simultaneously highlight healthy, critical structures like nerves and ureters. This 'surgery by colors' approach aims to prevent accidental severing and reduce major complications like incontinence or impotence.